NEPH - Nephros' HDF assist module gets FDA nod for hemodiafiltration therapy for kidney disease patients

Nephros (NASDAQ:NEPH) said the U.S. Food and Drug Administration granted 510(k) clearance to its second-generation HDF Assist Module to provide hemodiafiltration (HDF) therapy to patients with end-stage renal disease (ESRD). The company said its HDF Assist Module is the first and only device in the U.S. cleared to provide HDF therapy to patients with ESRD. "Our HDF Assist Module is an innovation that offers practitioners the opportunity to use an existing hemodialysis (HD) machine to provide HDF therapy without the purchase of a new, costly machine," said Nephros President and CEO Andy Astor. NEPH +1.32% to $2.30 premarket May 17

For further details see:

Nephros' HDF assist module gets FDA nod for hemodiafiltration therapy for kidney disease patients